Patents by Inventor Hadas Reuveni

Hadas Reuveni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Short peptides from the ‘2loop’ of 7 transmembrane receptor which selectively modulate signal transduction
    Patent number: 7683031
    Abstract: The present invention concerns compounds comprising, within short sequences from a specific regions of the 7TM receptor, that can modulate 7TM receptor-associated signal. The present invention further concerns methods for stimulation angiogenesis by administration of peptides derived from the EDG3 7TM-receptor.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: March 23, 2010
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Shmuel Ben-Sasson, Hadas Reuveni
  • NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20100056635
    Abstract: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.
    Type: Application
    Filed: December 4, 2007
    Publication date: March 4, 2010
    Inventors: Hadas Reuveni, Alexander Levitzki, Lilach Steiner, Revital Sasson, Iris Ben-David, Avi Weissberg
  • Short peptides from the '2nd loop' of 7 transmembrane receptor which selectively modulate signal transduction
    Publication number: 20060257869
    Abstract: The present invention concerns compounds comprising, within short sequences from a specific regions of the 7TM receptor, that can modulate 7TM receptor-associated signal. The present invention further concerns methods for stimulation angiogenesis by administration of peptides derived from the EDG3 7TM-receptor.
    Type: Application
    Filed: September 3, 2003
    Publication date: November 16, 2006
    Applicant: Children's Hospital
    Inventors: Shmuel Ben-Sasson, Hadas Reuveni
  • Protein kinase inhibitors
    Patent number: 6949565
    Abstract: Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases, are also disclosed.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: September 27, 2005
    Assignees: Develogen Israel Ltd., Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Nurit Livnah, Alexander Levitzki, Hadas Reuveni
  • Treatment of cancer
    Publication number: 20040121952
    Abstract: The present invention concerns methods for the treatment of solid tumors by the inhibition of Lyn associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn. The present invention further concerns a method for the treatment of cancer by the administration of compounds comprising Lyn-derived peptides.
    Type: Application
    Filed: June 6, 2003
    Publication date: June 24, 2004
    Applicants: Children's Medical Center Corporation, Yissum Research and Development
    Inventors: Shmuel Ben-Sasson, Hadas Reuveni
  • Protein kinase inhibitors
    Publication number: 20040019077
    Abstract: Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases, are also disclosed.
    Type: Application
    Filed: April 3, 2003
    Publication date: January 29, 2004
    Inventors: Nurit Livnah, Alexander Levitzki, Hadas Reuveni
  • Semipeptoid farnesyl protein transferase inhibitors and analogs thereof
    Patent number: 5990277
    Abstract: A farnesyl protein transferase (i.e., farnesyltransferase) inhibitors formed as peptoid and semipeptoid peptidomimetic compounds derived from a farnesyltransferase universal recognition tetrapeptide sequence CAAX (i.e., CAAX motif) and analogs thereof, and to the use of these compounds and analogs and ester derivatives thereof as chemotherapeutic agents in oncogenic or non-oncogenic Ras associated cancers and proliferative diseases.
    Type: Grant
    Filed: September 3, 1996
    Date of Patent: November 23, 1999
    Assignee: Yissum Research Development Company of the Herbrew University of Jerusalem
    Inventors: Alexander Levitzki, Chaim Gilon, Hadas Reuveni